Table 2.
Follow-up characteristics by clinic
| CHU Sourô Sanou | CePReF | CHUSO | CIRBA | Total | D:A:D cohort [5] | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||||
| No. of participants | 4903 | 5631 | 1282 | 3114 | 14 930 | 17 954 | ||||||
| Follow-up duration (years) | 6.3 | (3.3–9.4) | 5.5 | (3.0–7.8) | 4.7 | (3.0–6.1) | 5.8 | (3.0–8.4) | 5.7 | (3.1–8.2) | 6.1 | |
| Frequency of kidney assessments (per year) | 2.0 | (1.8–2.3) | 1.8 | (1.5–2.2) | 0.8 | (0.7–1.1) | 2.1 | (1.9–2.3) | 1.9 | (1.6–2.2) | 3 | (2–4) |
| Creatinine (μmol/L) | 73.0 | (64.0–83.0) | 61.9 | (53.0–79.6) | 79.6 | (70.7–88.4) | 69.0 | (57.5–83.1) | 70.7 | (60.6–81.0) | ||
| eGFR (mL/min/1.73 m2) | 94.2 | (81.1–106.5) | 105.4 | (87.8–115.2) | 86.6 | (74.0–101.1) | 100.5 | (85.0–111.7) | 98.8 | (83.4–111.2) | ||
| CKD | ||||||||||||
| Developed CKD [n (%)] | 233 | 4.8 | 227 | 4.0 | 43 | 3.4 | 157 | 5.0 | 660 | 4.4 | 641 | 3.6 |
| Incidence of CKD [per 1000 PYFU (95% CI)] | 7.7 | (6.8–8.8) | 7.2 | (6.3–8.1) | 7.5 | (5.5–10.1) | 9.3 | (7.9–10.8) | 7.8 | (7.2–8.4) | 6.2 | (5.7–6.7) |
CHU Sourô Sanou, University Teaching Hospital Sourô Sanou in Bobo Dioulasso, Burkina Faso; CePReF, the Centre de Prise en Charge, de Recherche et de Formation; CIRBA, Centre Intégré de Recherches Biocliniques d’Abidjan, Abidjan, Côte d’Ivoire; CHUSO, University Teaching Hospital Sylvanus Olympio, Lomé, Togo; ART, antiretroviral treatment; eGFR, estimated glomerular filtration rate; CI, confidence interval; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; PYFU, person-years of follow-up.
Values are median (interquartile range) unless specified otherwise.